Vanderbilt Health has successfully implanted a novel heart monitoring device, the V-LAP, in a patient for the first time as part of an ongoing clinical trial. The study is currently being conducted at only five centres across the United States.
The V-LAP device monitors pressure within the left atrium of the heart in real time. This helps healthcare teams make more informed decisions regarding treatment and medication adjustments, which may lead to better patient outcomes.
Unlike other tools such as CardioMEMS and Cordella, which provide indirect pressure readings, the V-LAP offers direct measurements. In addition, it includes a patient self-management portal. This allows individuals to access their heart pressure data and adjust their medication based on pre-set guidance from their clinicians. The system is designed to give patients more control over their condition, similar to how blood glucose monitors are used in diabetes care.
The new technology allows to reduce in-person visits to the main campus, can now be monitored remotely and adjust his medication using notifications from his mobile phone.
The Heart Failure Remote Patient Management Devices Programme has benefited over 100 patients from similar implantable devices. The V-LAP procedure typically takes between 45 and 60 minutes to complete.
